|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||20.84|
|Forward Dividend & Yield||1.03 (3.35%)|
|1y Target Est||N/A|
Smoking, which causes many lung cancer cases, has made advanced lung cancer a big market for pharmaceutical companies, and the competition has been fierce.
Merck surged to a three-month high Tuesday on strong results for its immuno-oncology and chemotherapy regimen in lung cancer.
Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.
Prothena's (PRTA) stock tumbles more than 18% due to a pipeline setback. The company depends heavily on the success of its two candidates.
Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.
In 3Q17, AbbVie (ABBV) reported global sales of nearly $276 million for its hepatitis C (or HCV) portfolio, which reflected a 27.7% operational fall and a 26.8% reported fall year-over-year (or YoY). The company reported HCV sales of close to $60 million from the US market in 3Q17, a YoY fall of ~19.5%. AbbVie also reported HCV sales of close to $216 million from international markets in 3Q17, a YoY fall of 29.8% on an operational basis and a fall of 28.7% on a reported basis.
General Electric Company's (GE) segment GE Healthcare will now help to create a digital platform with Roche to advance medicinal treatments particularly for cancer and critical care patients.
Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.
In a relatively slow week, Allergan's (AGN) job cut announcement remained the key highlight while Pfizer's collaboration agreements with Sangamo and Arvinas were also in focus.
We take a look at a few Large Cap drug stocks with a favorable combination of Zacks Rank and VGM Score. The stocks are poised to carry on their bull run this year too.
The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.